De novo exon 18 G724S point mutation may be sensitive to Gefitinib

Osimertinib has been approved for lung cancer patients with acquired T790M point mutations after 1st or 2nd generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). An EGFR mutation examination utilized amplification refractory mutation specific (ARMS) polymerase chain reactions (PCRs) and Scorpion technologies for detection; direct sequencing was performed if a negative result was found in the ARMS PCR. Initially, chemotherapy was encouraged but she refused. [...]Gefitinib was prescribed in December 2011.